Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($)	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 2,625	$ 53,114	$ 3,039,163	$ (4,894,881)	$ (11,622)	$ (1,811,601)
Beginning balance, shares at Dec. 31, 2019	262,500	5,311,414
September 2020 private placement		$ 369	227,131			227,500
September 2020 private placement, shares		36,871
December 2020 private placement	$ 2,212		258,288			260,500
December 2020 private placement, shares	221,225
Acquisition of Tikkun Pharma IP		$ 5,720	1,894,826			1,900,546
Acquisition of Tikkun Pharma IP, shares		571,987
Conversion of Series B preferred shares	$ 30,417	$ 4,030	4,781,742			4,816,189
Conversion of Series B preferred shares, shares	3,041,682	402,988
Exchange of warrants for common shares		$ 3,301	838,577			841,878
Exchange of warrants for common shares, shares		330,122
Conversion of related party advance and notes payable		$ 5,130	674,439			679,569
Conversion of related party advance and notes payable, shares		512,978
Common stock issued for accounts payable		$ 4,330	752,193			756,523
Common stock issued for accounts payable, shares		433,047
Warrants issued in conjunction with notes payable			32,149			32,149
Beneficial conversion feature issued with note payable			17,851			17,851
Common stock issued in conjunction with note payable modification		$ 216	101,497			101,713
Common stock issued in conjunction with note payable modification, shares		21,625
Stock-based compensation			1,977,155			1,977,155
Conversion of Series B preferred stock to common stock	$ (2,500)	$ 2,500
Conversion of Series B preferred stock to common stock, shares	(250,000)	250,000
Merger with Ameri Holdings, Inc		$ 22,241	627,759			650,000
Merger with Ameri Holdings, Inc, shares		2,224,077
Foreign currency translation gain					(169,655)	(169,655)
Net Loss				(6,864,676)		(6,864,676)
Ending balance, value at Dec. 31, 2020	$ 32,754	$ 100,951	15,222,770	(11,759,557)	(181,277)	3,415,641
Ending balance, shares at Dec. 31, 2020	3,275,407	10,095,109
Conversion of Series B preferred shares	$ (32,754)	$ 32,754
Conversion of Series B preferred shares, shares	(3,275,407)	3,275,407
Common stock issued in conjunction with note payable modification
Foreign currency translation gain					150,475	150,475
Net Loss				(48,976,896)		(48,976,896)
January 2021 registered direct offering		$ 22,213	4,594,874			4,617,087
January 2021 registered direct offering, shares		2,221,334
February 2021 registered direct offering		$ 30,070	6,986,331			7,016,401
February 2021 registered direct offering, shares		3,007,026
Consideration paid pursuant to amalgamation agreement		$ 99,512	38,942,770			39,042,282
Consideration paid pursuant to amalgamation agreement, shares		9,951,217
Warrant exercise		$ 26,431	3,258,740			3,285,171
Warrant exercise, shares		2,643,047
Cashless options exercise		$ 1,342	(1,342)
Cashless options exercise, shares		134,246				143,796
Induced conversion of warrants and options to Common Stock		$ 10,154	1,115,137			$ 1,125,291
Induced conversion of warrants and options to Common Stock, shares		1,015,315
Stock-based compensation			12,597,001			12,597,001
Common stock issued in lieu of cash for services		$ 141	33,326			33,467
Common stock issued in lieu of cash for services, shares		14,121
Common stock issued pursuant to exercise of warrant put rights		$ 2,217	(2,217)
Common stock issued pursuant to exercise of warrant put rights, shares		221,653
Ending balance, value at Dec. 31, 2021		$ 325,785	$ 82,747,390	$ (60,736,453)	$ (30,802)	$ 22,305,920
Ending balance, shares at Dec. 31, 2021		32,578,475